246 filings
8-K
ELTP
Elite Pharmaceuticals Inc
14 Feb 24
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024
4:55pm
8-K
ELTP
Elite Pharmaceuticals Inc
26 Dec 23
Regulation FD Disclosure
4:20pm
8-K
ELTP
Elite Pharmaceuticals Inc
12 Dec 23
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR® to Marketing Partner Prasco, LLC
4:20pm
8-K
ELTP
Elite Pharmaceuticals Inc
14 Nov 23
Results of Operations and Financial Condition
5:22pm
8-K
ELTP
Elite Pharmaceuticals Inc
25 Sep 23
Regulation FD Disclosure
4:15pm
8-K
39em4o9
7 Sep 23
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
4:05pm
8-K
bauqw3dgdt dpqw
14 Aug 23
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024
5:30pm
8-K
svl c189cl7srlp7
17 Jul 23
Changes in Registrant's Certifying Accountant
4:15pm
8-K
xkuoc vcbz
29 Jun 23
Results of Operations and Financial Condition
5:15pm
8-K
umt 0jztxs
3 May 23
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
4:15pm
8-K
asq86ns
20 Apr 23
Regulation FD Disclosure
10:05am
8-K
xkc1div6oh0a wp
28 Feb 23
Departure of Directors or Certain Officers
4:36pm
8-K
jp2kv9c5r
14 Feb 23
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023
5:10pm
8-K
00oo gnmims72pt8y0p
22 Dec 22
Regulation FD Disclosure
4:21pm
8-K
nqhzwwdnq 3adw
28 Nov 22
Entry into a Material Definitive Agreement
4:05pm
8-K
u1dhxcgv0chsn5a
15 Nov 22
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023
12:36pm
8-K
y4xutoeo
10 Nov 22
Termination of a Material Definitive Agreement
4:15pm
8-K
vt8l00g5u4o
2 Nov 22
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
4:30pm
8-K
l7r8s9
7 Sep 22
Entry into a Material Definitive Agreement
4:35pm
8-K
vsdagp
26 Aug 22
Termination of a Material Definitive Agreement
4:45pm